Prevalence and Associated Factors of Non-Alcoholic Fatty Liver Disease in People Living with HIV-1.

IF 0.8 4区医学 Q4 IMMUNOLOGY

Current HIV Research Pub Date : 2025-03-24 DOI:10.2174/011570162X340918250312040500

Fatma Nur Karatas, Caglayan Keklikkiran, Yusuf Yilmaz, Pınar Ay, Volkan Korten, Uluhan Sili

{"title":"Prevalence and Associated Factors of Non-Alcoholic Fatty Liver Disease in People Living with HIV-1.","authors":"Fatma Nur Karatas, Caglayan Keklikkiran, Yusuf Yilmaz, Pınar Ay, Volkan Korten, Uluhan Sili","doi":"10.2174/011570162X340918250312040500","DOIUrl":null,"url":null,"abstract":"Background: Modern Anti-retroviral Therapy (ART) prevents disease progression in people living with HIV. Due to the increasing age of people living with HIV, the detection and management of comorbidities has become more important.Objective: In this study, we aimed to detect the prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) and associated risk factors among people living with HIV followed up in our center.Methods: This single-center, cross-sectional study included people living with HIV, on ART for ≥1 year and virologic suppression for ≥6 months, presenting for routine follow-up between October 1, 2021, and April 1, 2022. Participants with a concurrent etiology for hepatic steatosis were excluded. Transient elastography (TE) was performed. NAFLD was defined as a controlled attenuation parameter (CAP) ≥248 dB/m; significant fibrosis (≥F2) was defined as liver stiffness measurement ≥7.1 kPa.Results: A total of 102 people living with HIV (84% men; median age, 39 years [IQR 33-52.5]) were enrolled. The treatment regimen of all participants included a nucleos(t)ide reverse transcriptase inhibitor and an integrase strand transfer inhibitor. TE analysis indicated NAFLD in 28 (27.5%) and fibrosis in 9 (8.8%; 6 with NAFLD) participants. In multivariable analysis, type two diabetes (OR:5.7 [95% CI 1.4-22.2], p=0.013), larger waist circumference (OR:1.1 [95% CI 1.03-1.16], p=0.007), higher alanine aminotransferase (OR:1.05 [95% CI 1.01-1.09], p=0.018), and higher thyroid stimulating hormone (OR:3.1 [95% CI 1.4-6.8], p=0.005] were independently associated with NAFLD.Conclusion: We observed a significant prevalence of NAFLD among people living with HIV followed up in our center. The high prevalence of NAFLD in our sample mirrors that of the general population, likely due to rising rates of metabolic dysfunction. Our findings highlight the importance of timely screening and implementation of management strategies for NAFLD in this population.","PeriodicalId":10911,"journal":{"name":"Current HIV Research","volume":" ","pages":""},"PeriodicalIF":0.8000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current HIV Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/011570162X340918250312040500","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Modern Anti-retroviral Therapy (ART) prevents disease progression in people living with HIV. Due to the increasing age of people living with HIV, the detection and management of comorbidities has become more important.

Objective: In this study, we aimed to detect the prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) and associated risk factors among people living with HIV followed up in our center.

Methods: This single-center, cross-sectional study included people living with HIV, on ART for ≥1 year and virologic suppression for ≥6 months, presenting for routine follow-up between October 1, 2021, and April 1, 2022. Participants with a concurrent etiology for hepatic steatosis were excluded. Transient elastography (TE) was performed. NAFLD was defined as a controlled attenuation parameter (CAP) ≥248 dB/m; significant fibrosis (≥F2) was defined as liver stiffness measurement ≥7.1 kPa.

Results: A total of 102 people living with HIV (84% men; median age, 39 years [IQR 33-52.5]) were enrolled. The treatment regimen of all participants included a nucleos(t)ide reverse transcriptase inhibitor and an integrase strand transfer inhibitor. TE analysis indicated NAFLD in 28 (27.5%) and fibrosis in 9 (8.8%; 6 with NAFLD) participants. In multivariable analysis, type two diabetes (OR:5.7 [95% CI 1.4-22.2], p=0.013), larger waist circumference (OR:1.1 [95% CI 1.03-1.16], p=0.007), higher alanine aminotransferase (OR:1.05 [95% CI 1.01-1.09], p=0.018), and higher thyroid stimulating hormone (OR:3.1 [95% CI 1.4-6.8], p=0.005] were independently associated with NAFLD.

Conclusion: We observed a significant prevalence of NAFLD among people living with HIV followed up in our center. The high prevalence of NAFLD in our sample mirrors that of the general population, likely due to rising rates of metabolic dysfunction. Our findings highlight the importance of timely screening and implementation of management strategies for NAFLD in this population.

查看原文本刊更多论文

HIV-1感染者非酒精性脂肪肝患病率及相关因素

背景：现代抗逆转录病毒治疗（ART）可预防艾滋病毒感染者的疾病进展。由于艾滋病毒感染者的年龄越来越大，合并症的检测和管理变得越来越重要。目的：在本研究中，我们旨在检测非酒精性脂肪性肝病（NAFLD）在我们中心随访的HIV感染者中的患病率及其相关危险因素。方法：这项单中心横断面研究纳入了接受抗逆转录病毒治疗≥1年且病毒学抑制≥6个月的艾滋病毒感染者，于2021年10月1日至2022年4月1日进行常规随访。同时患有肝脂肪变性的参与者被排除在外。进行瞬态弹性成像（TE）。NAFLD定义为可控衰减参数(CAP)≥248 dB/m；肝刚度≥7.1 kPa为显著纤维化（≥F2）。结果：共102例HIV感染者(84%为男性；中位年龄为39岁[IQR 33-52.5])。所有参与者的治疗方案包括核苷(t)逆转录酶抑制剂和整合酶链转移抑制剂。TE分析显示NAFLD 28例（27.5%），纤维化9例（8.8%）；6名NAFLD参与者。在多变量分析中，2型糖尿病（OR:5.7 [95% CI 1.4-22.2], p=0.013）、较大腰围（OR:1.1 [95% CI 1.03-1.16], p=0.007）、较高的丙氨酸转氨酶（OR:1.05 [95% CI 1.01-1.09], p=0.018）和较高的促甲状腺激素（OR:3.1 [95% CI 1.4-6.8], p=0.005）与NAFLD独立相关。结论：我们观察到在我们中心随访的HIV感染者中NAFLD的显著流行。我们样本中NAFLD的高患病率反映了一般人群的高患病率，可能是由于代谢功能障碍的发生率上升。我们的发现强调了在这一人群中及时筛查和实施NAFLD管理策略的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current HIV Research 医学-病毒学

CiteScore

1.90

自引率

10.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Current HIV Research covers all the latest and outstanding developments of HIV research by publishing original research, review articles and guest edited thematic issues. The novel pioneering work in the basic and clinical fields on all areas of HIV research covers: virus replication and gene expression, HIV assembly, virus-cell interaction, viral pathogenesis, epidemiology and transmission, anti-retroviral therapy and adherence, drug discovery, the latest developments in HIV/AIDS vaccines and animal models, mechanisms and interactions with AIDS related diseases, social and public health issues related to HIV disease, and prevention of viral infection. Periodically, the journal invites guest editors to devote an issue on a particular area of HIV research of great interest that increases our understanding of the virus and its complex interaction with the host.